Eli Lilly and Company (LLY) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Eli Lilly And Company.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.105 -- 00:00:05.709 Good morning. Thank you for joining us for Eli Lilly and Company's Q2 2026 earnings call. 00:00:05.709 -- 00:00:09.191 I'm Mike Czapar, Senior Vice President of Advice to Relations. 00:00:09.191 -- 00:00:14.414 Joining me on today's call are Dave Ricks, Lilly's Chair and CEO, Lucas Montarce, Chief 00:00:14.414 -- 00:00:19.758 Financial Officer, Dr. Dan Skovronsky, Chief Scientific and Product Officer, Adrian 00:00:19.758 -- 00:00:25.282 Brown, President of Lilly Immunology, Dr. Carol Ho, President of Lilly Neuroscience, 00:00:25.282 -- 00:00:30.050 Ilya Yuffa, President of Lilly USA and Global Customer Capabilities, 00:00:30.050 -- 00:00:34.591 President of Lilly Oncology and Head of Business Development, Patrick Johnson, President 00:00:34.591 -- 00:00:39.413 of Lilly International, and Ken Kuster, President of Lilly Cardiometabolic Health. 00:00:39.413 -- 00:00:43.314 During this call, we anticipate making projections and forward-looking statements based 00:00:43.314 -- 00:00:47.415 on our current expectations. Our actual results could differ materially due to various 00:00:47.415 -- 00:00:50.676 factors, including those listed on slide four. 00:00:50.676 -- 00:00:54.697 Additional information concerning factors that could cause actual results to differ materially 00:00:54.697 -- 00:00:59.265 is contained in our latest Form 10-K and subsequent filing with the SEC. 00:00:59.265 -- 00:01:02.567 The information we provide about our products and pipeline is for the benefit of the 00:01:02.567 -- 00:01:07.611 investment community. It is not intended to be promotional or otherwise influence prescribing 00:01:07.611 -- 00:01:12.814 decisions. Our commentary today will focus on our non-GAAP financial measures. 00:01:12.814 -- 00:01:15.23...